Epidermal growth factor receptor targeting.
Dr. Jose Baselga (Hospital Vall d'Hebron, Barcelona, Spain) chaired and led a discussion of several posters on the marking and detection of the epidermal growth factor receptor (EGFR), and compounds that target this receptor. The posters consisted of biological studies and phase I trials with EGFR tyrosine kinase (TK) inhibitors. The basis of EGFR targeting in cancer therapy depends on the overexpression in malignancy and potential inhibition with antibodies and TK inhibitors. Correlations have been made between receptor function and inhibition of growth.
McKinnon
C
C
Current Drugs Ltd, Middlesex House, 34-42 Cleveland Street, London W1P 6LB, United Kingdom. colinm@cursci.co.uk